Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
siRNA (DLL3)
- Development stage
- Preclinical
- Lead developer
- Hokkaido University
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous, Inhalation
01
Overview
siRNA (DLL3) refers to small interfering RNA molecules designed to specifically target and silence the expression of Delta-like protein 3 (DLL3). DLL3 is a Notch pathway ligand that is highly upregulated in small cell lung cancer (SCLC) and other neuroendocrine tumors, where it is thought to inhibit Notch signaling and promote tumorigenesis. By utilizing the RNA interference (RNAi) pathway, these siRNA molecules induce the degradation of DLL3 mRNA, thereby reducing DLL3 protein levels. Preclinical research has demonstrated that knockdown of DLL3 in SCLC cell lines leads to inhibited cell proliferation, migration, and invasion, potentially through the modulation of Notch1 signaling and the downregulation of the epithelial-mesenchymal transition (EMT) marker Snail.
- Other names
- DLL3 siRNADLL-3 siRNADLL 3 siRNAanti-DLL3 siRNAanti-DLL-3 siRNAanti-DLL 3 siRNADelta-like protein 3 siRNA
02
Targets
Innate immune RNA sensorsDLL3 (Delta-like ligand 3)
Beyond the preview
Go deeper on siRNA (DLL3).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on siRNA (DLL3).